Sientra (NASDAQ:SIEN) and Inogen (NASDAQ:INGN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.
This table compares Sientra and Inogen’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Sientra and Inogen’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sientra||$36.54 million||16.97||-$64.02 million||($2.82)||-7.73|
|Inogen||$249.44 million||17.93||$21.00 million||$1.31||159.87|
Inogen has higher revenue and earnings than Sientra. Sientra is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
89.2% of Sientra shares are owned by institutional investors. Comparatively, 96.5% of Inogen shares are owned by institutional investors. 31.0% of Sientra shares are owned by insiders. Comparatively, 5.3% of Inogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a summary of recent ratings for Sientra and Inogen, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sientra presently has a consensus price target of $24.14, suggesting a potential upside of 10.70%. Inogen has a consensus price target of $238.80, suggesting a potential upside of 14.02%. Given Inogen’s higher possible upside, analysts clearly believe Inogen is more favorable than Sientra.
Volatility & Risk
Sientra has a beta of -0.78, indicating that its share price is 178% less volatile than the S&P 500. Comparatively, Inogen has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.
Inogen beats Sientra on 11 of the 14 factors compared between the two stocks.
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline-filled breast implant sizers to identify the correct style and size of implants; and non-breast tissue expanders for expanding tissue and skin surface area for burn care and other reconstructive use. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.